Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Trends And Growth Drivers Point To Strong Future Potential
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Growth Analysis: How Will Revenue Expand During The Forecast Period?
The market for human epidermal growth factor receptor 2 (HER2)-positive gastric cancer has experienced consistent expansion in recent times. Forecasts indicate an increase from $1.31 billion in 2025 to $1.37 billion in 2026, reflecting a compound annual growth rate (CAGR) of 4.6%. Several factors contributed to this past growth, including a scarcity of targeted treatment options, dependence on standard chemotherapy and radiation approaches, limited understanding of HER2-positive gastric cancer, reduced availability of specialized medical facilities, and a sluggish uptake of immunotherapeutic strategies.
The market for human epidermal growth factor receptor 2 (HER2)-positive gastric cancer is projected to undergo consistent expansion over the coming years. By 2030, it is anticipated to reach $1.64 billion, reflecting a compound annual growth rate (CAGR) of 4.6%. This forecasted growth is fueled by several factors, including the development of innovative antibody-drug conjugates, a rise in clinical trials for HER2-targeted therapies, improvements in healthcare infrastructure within emerging markets, the advancement of precision medicine alongside biomarker testing, and the growing number of ambulatory surgery centers and specialized oncology clinics. Key trends shaping this period involve the increased uptake of HER2-targeted treatments, heightened awareness of gastric cancer subtypes, broader application of immunotherapy and monoclonal antibodies, a shift toward personalized therapeutic strategies, and a stronger emphasis on early detection and diagnostic tests.
Download A Free Sample Report For Comprehensive Market Insights:
Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Growth Factors Supporting Long-Term Expansion
The increasing uptake of targeted cancer therapies is anticipated to drive expansion in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market going forward. Targeted therapy, often referred to as precision medicine, involves the use of specific agents or substances designed to hinder cancer growth by zeroing in on key molecules involved in tumor progression. The growing reliance on targeted therapy stems largely from enhancements in genetic profiling, which enable more accurate treatments tailored to a patient’s distinct tumor characteristics, resulting in greater efficacy and reduced adverse effects. Within HER2-positive gastric cancer, this therapeutic method works by directly targeting the HER2 protein—overexpressed in these malignancies—thereby decelerating disease advancement and improving patient outcomes. For example, in February 2024, the Personalized Medicine Coalition, a US-based professional membership organization, reported that the Food and Drug Administration (FDA) approved 16 new personalized treatments in 2023, including seven for cancer and three for other diseases and conditions, marking an increase from six approvals in 2022. Thus, the growing adoption of targeted cancer therapies is fueling expansion in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market.
Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Segment Landscape: Which Areas Lead Market Development?
The human epidermal growth factor receptor 2 (her2)-positive gastric cancer market covered in this report is segmented –
1) By Therapy: Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy
2) By Stage: Stage I, Stage II, Stage III, Stage IV
3) By End-User: Ambulatory Surgery Centers, Hospitals And Specialty Clinics, Other End-Users
Subsegments:
1) By Chemotherapy: Fluoropyrimidines, Platinum-Based Agents, Taxanes, Irinotecan, Anthracyclines
2) By Immunotherapy: Immune Checkpoint Inhibitors, Monoclonal Antibodies, Cancer Vaccines, Cytokine-Based Therapies
3) By Radiation Therapy: External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Stereotactic Body Radiation Therapy, 3D Conformal Radiation Therapy
4) By Targeted Therapy: HER2-Targeted Therapies, Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, mTOR Inhibitors, PI3K/AKT/mTOR Pathway Inhibitors
Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Industry Trends Shaping Future Revenue Growth
Major pharmaceutical corporations dominating the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market are actively pursuing regulatory approvals for cutting-edge therapies, particularly advanced immunotherapy-enhanced combination strategies that incorporate immune checkpoint inhibitors alongside targeted agents and chemotherapy, aiming to substantially boost patient outcomes in first-line therapeutic contexts. This sophisticated approach for advanced immunotherapy-enhanced combination regimens functions by engaging the immune system through inhibition of programmed death (PD)-1 or its ligand PD-L1 interactions, while concurrently targeting HER2 receptors and applying chemotherapeutic drugs, thus intensifying anti-tumor effects and extending survival rates. A notable example occurred in March 2025 when Merck & Co., Inc., a biopharmaceutical firm headquartered in the United States, secured approval from the U.S. Food and Drug Administration (FDA) for its product pembrolizumab (Keytruda) administered jointly with trastuzumab and chemotherapy, designated as an initial treatment for adult patients diagnosed with HER2-positive unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma exhibiting PD-L1 expression on tumor cells. Results from this newly authorized combination therapy revealed a notable enhancement in median progression-free survival and overall survival when compared against conventional treatment protocols, and with an overall response rate reaching 73% coupled with an extended median duration of response, this intervention marks a transformative shift in managing advanced HER2-positive gastric malignancies.
Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Industry Leaders And Market Competition
Major companies operating in the human epidermal growth factor receptor 2 (her2)-positive gastric cancer market are Pfizer Inc., Roche Holding AG, Merck & Co Inc., Bayer Aktiengesellschaft, Eli Lilly and Company, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Amgen Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Genentech Inc., Ono Pharmaceutical Co Ltd., Shanghai Henlius Biotech Inc., MacroGenics Inc., Hutchison Medipharma Limited , ALX Oncology Holdings Inc., Taiho Pharmaceutical Co Ltd., Ambrx Biopharma Inc., LintonPharm Co Ltd.
Access The Complete Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Report:
Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human epidermal growth factor receptor 2 (her2)-positive gastric cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
